Literature DB >> 839864

Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease.

M D Muenter, N S Sharpless, G M Tyce, F L Darley.   

Abstract

The clinical, biochemical, and pharmacologic responses to L-dopa were studied in 87 patients with Parkinson's disease. Eleven of the 87 patients had a long-duration response, 39 had a short-duration response, and 37 had a combination of both. Thirty-four of the 39 patients with short-duration response to L-dopa experienced a consistent and reproducible sequence of clinical and biochemical events after each dose, characterized by improvement of parkinsonism and a single phase of dystonia occurring during or shortly after the peak of dopa concentration in plasma and during maximal clinical improvement. We have called this the I-D-I- response, for Parkinsonism-Improvement-Dystonia-Improvement-Parkinsonism. The remaining five patients all had the onset of the disease at an unusually young age and showed a distinctly different response pattern consisting of a first phase of dystonia, before there was any improvement, followed by a phase of improvement without dystonia and then by a second phase of dystonia before the abrupt return of parkinsonism. We have called this the D-I-D response, for Parkinsonism-Dystonia-Improvement-Dystonia-Parkinsonsim. Dystonia occurs in the D-I-D- response when the concentration of dopa in plasma passes through a critical but relatively low level, whereas it remains absent as long as the concentration of dopa remains above that level. In the I-D-I- response, dystonia is avoided by keeping the plasma concentration of dopa low, in the D-I-D- response by keeping it high. It is postulated that in the D-I-D response postsynaptic depolarization blockade due to supramaximal stimulation of the neuronal system mediating dystonia occurs, whereas in the I-D-I response the postsynaptic members of the same neuronal population respond with excitation but not with depolarization blockade.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 839864

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  29 in total

Review 1.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  The influence of levodopa-induced dyskinesias on manual tracking in patients with Parkinson's disease.

Authors:  Sarah Lemieux; Mehrdad Ghassemi; Mandar Jog; Roderick Edwards; Christian Duval
Journal:  Exp Brain Res       Date:  2006-08-30       Impact factor: 1.972

3.  Levodopa-induced dyskinesia in Parkinson disease: A population-based cohort study.

Authors:  Pierpaolo Turcano; Michelle M Mielke; James H Bower; Joseph E Parisi; Jeremy K Cutsforth-Gregory; J Eric Ahlskog; Rodolfo Savica
Journal:  Neurology       Date:  2018-11-07       Impact factor: 9.910

Review 4.  Parkinson's disease.

Authors:  E C Wolters; D B Calne
Journal:  CMAJ       Date:  1989-03-01       Impact factor: 8.262

5.  Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease.

Authors:  B Henry; J M Brotchie
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

Review 6.  Parkinson's disease in 1984: an update.

Authors:  A E Lang; R D Blair
Journal:  Can Med Assoc J       Date:  1984-11-01       Impact factor: 8.262

7.  Levodopa-induced dyskinesia and thalamotomy.

Authors:  H Narabayashi; F Yokochi; Y Nakajima
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

Review 8.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

Review 9.  Levodopa-induced dyskinesias and their management.

Authors:  Francesca Del Sorbo; Alberto Albanese
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

Review 10.  Methods of managing levodopa-induced dyskinesias.

Authors:  L T Giron; W C Koller
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.